Aug 25, 2021
FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions in legal psychedelics and medical cannabis, announces today it has entered a definitive agreement to acquire 100% of the issued and outstanding shares Lucid Psycheceuticals Inc. (“Lucid”)...
June 14, 2021
Lucid Psycheceuticals Announces Exclusive License to Develop Cutting-Edge Neurodegenerative Disease Therapeutics
Lucid Psycheceuticals Inc. (Lucid), a psychedelics-inspired company focusing on total brain health, today announced that it has entered into a world-wide license agreement with University Health Network (UHN), Canada’s top research hospital, granting Lucid exclusive rights to novel compounds for therapeutic applications in neurodegenerative disorders.
In The News
In The News
Aug 18, 2021
Lucid Psycheceuticals focusing on Total Brain Health
Closely-held Lucid Psycheceuticals’ next generation approach to total brain health is targeting the interface between mental health and neurodegenerative disorders with therapeutic products inspired by psychedelics and new chemical entities.